400-815-1117
2026-01-15
International pharmaceutical leaders and investors gathered in San Francisco on Sunday to explore partnership opportunities with Chinese biotech companies, as the country's out-licensing deals exceeded $130 billion last year and its contribution to the global drug pipeline reached 30 percent.
国际制药界领袖与投资者周日齐聚旧金山，探索与中国生物科技企业的合作机遇。去年中国医药对外授权交易额突破1300亿美元，对全球创新药研发管线贡献度已达30%。
Organized by the Zhongguancun FIC Innovative Drug Strategic Development Alliance, the 2026 China FIC Innovation and Collaboration Summit served as a global roadshow and launch platform for key Chinese innovative drug projects, facilitating connections between Chinese pharmaceutical companies and international industry leaders while promoting increased multinational investment in China's biotech sector.
由ZFIC联盟主办的2026中国FIC创新与合作峰会，为中国重点创新药项目提供了全球路演与发布平台，促进了中国药企与国际产业领袖的对接，并推动跨国资本加大对中国生物科技领域的投资。
"Our journey — from humble 'Me-Too' and 'Me-Better' to transformative 'First-in-Class' — tells a story not just of scientific progress, but of an entirely new ecosystem and a transformed model of global partnership," said the director-general of Beijing Investment Promotion Service Center during the summit."
我们正在从'Me too'和'Me better'到具有变革性的“First in class”转变，这不仅是一个科学进步的故事，更是一个全新生态系统和全球化合作模式转型的故事。"北京市投资促进服务中心主任在峰会中表示。
She called the event a "vital two-way bridge" that showcases China's potential to the world while connecting global expertise with Chinese innovation, and said that China's pharmaceutical sector momentum rests on several fundamental pillars.China's massive unified market, with over 1.4 billion people and healthcare coverage for 1.33 billion citizens, provides unparalleled scale for clinical development and commercialization of innovative medicines. The country's regulatory framework has evolved to operate in full compliance with International Council for Harmonisation guidelines, matching leading global standards while balancing innovation incentives with accessibility through volume-based procurement and national reimbursement negotiations, the director-general said.
她称此次峰会为一座"至关重要的双向桥梁"，既向世界展示中国潜力，又将全球专业智慧与中国创新相连。她指出，中国医药行业的发展动能基于几大基石：中国拥有超过14亿人口的庞大统一市场，其中13.3亿公民享有医疗保障，为创新药的临床开发和商业化提供了无与伦比的规模优势；中国的监管体系已全面遵循国际人用药品注册技术协调会指南，既对标全球领先标准，又通过带量采购和国家医保谈判在创新激励与药物可及性间取得平衡。
The pace of regulatory approvals has accelerated dramatically, with Chinese authorities approving a record 76 innovative drugs in 2025 alone. These streamlined review timelines have created clearer pathways for synchronized global drug development and launches, she said.
药品审评审批速度已显著加快，仅2025年中国就创纪录地批准了76款创新药。这些简化的审评时间线为全球同步研发和上市创造了更清晰的路径。
China's emergence as a global research and development powerhouse is reflected in its out-licensing deals surpassing $130 billion last year, with approximately 30 percent of the worldwide innovative drug pipeline now being developed in China, according to the director.
中国作为全球研发强国的崛起，体现在去年对外授权交易额突破1300亿美元，且全球约30%的创新药研发管线来自中国。
Despite headwinds facing globalization and rising protectionism, Chinese Consul General in San Francisco Zhang Jianmin said that economic interdependence remains a global reality, with international collaboration essential for finding global solutions.
尽管面临全球化逆风和保护主义抬头，中国驻旧金山总领事张建敏表示，经济相互依存仍是全球现实，国际合作对寻求全球性解决方案至关重要。
"The biopharmaceutical sector is a case in point, because this sector depends so much on global supply chains, cross-border clinical research, data sharing and the spirits of working together among scientists and innovators from around the world," Zhang said."Many of the tasks ahead of us are so complex that they are often beyond the capability of any individual country working alone. China and the United States are the two leading economies and the two leading innovators. If our two countries, our experts and scientists, our industries, are able to work together, it will immeasurably increase the chance of success in getting the most important job done," he said.
"生物制药领域就是例证，该领域高度依赖全球供应链、跨境临床研究、数据共享以及全球科学家和创新者的协作精神。"他说，"我们面临的许多任务如此复杂，往往超出任何单一国家独立应对的能力。中美作为两大经济体和创新引领者，若两国专家、科学家及产业界能携手合作，将极大提升完成最重要任务的胜算。"
California State Treasurer Fiona Ma echoed this collaborative vision, highlighting the importance of leveraging technology to accelerate research and improve health outcomes. She said that California voters have consistently prioritized healthcare through statewide initiatives, approving bonds for stem cell research, children's hospitals and behavioral health services.
加州财长Fiona Ma呼应了这一合作愿景，强调利用技术加速研究、改善健康成果的重要性。她指出加州选民始终通过全州倡议优先保障医疗健康，批准了用于干细胞研究、儿童医院和行为健康服务的债券。
"So we have a lot of money now. We are investing in all of these areas. That's why we welcome the partnerships. We should not be doing research and development in our silos now. With the internet, with AI capabilities, we are better able to share our research," Ma said, "and that will expedite discoveries, increase people's health and longevity."
"因此我们现有充足资金正投入这些领域，这也是我们欢迎合作的原因。在互联网和人工智能时代，我们不应再固守孤岛进行研发，而应更好地分享研究成果，这将加速科学发现，增进人民健康与寿命。"
The summit highlighted China's decade-long transformation in pharmaceutical innovation. While the country's innovative drug pipeline has experienced explosive growth and become integral to the global pharmaceutical landscape, with 2025's cross-border licensing value doubling the previous year's scale, only a small percentage of China's new drug pipelines have been involved in transactions, indicating substantial untapped collaboration potential.
峰会凸显了中国医药创新十年的转型历程。虽然中国创新药管线呈爆炸式增长并已成为全球医药格局的重要组成部分，2025年跨境授权交易额更达上年规模两倍，但其中仅小部分新药管线参与交易，表明仍有巨大的合作潜力尚待开发。
The ZFIC Alliance designed the summit to address this gap by creating an efficient communication platform connecting international pharmaceutical companies, investment institutions and Chinese biotech enterprises. Nine representative projects were selected from nearly 30 roadshow applications for in-person pitching sessions, spanning multiple cutting-edge technology areas and designed to enhance international visibility and collaboration potential.
ZFIC联盟举办此次峰会正是为了填补这一空白，构建连接国际药企、投资机构与中国生物科技企业的高效沟通平台。从近30个路演申请中精选的9个代表性项目进行了现场推介，涵盖多个前沿技术领域，旨在提升国际能见度与合作潜力。
Joseph Scheeren, a member of the French National Academy of Pharmacy with over three decades of pharmaceutical industry experience across the US, Europe and Asia, offered an optimistic assessment of China's trajectory.
拥有逾三十年横跨美、欧、亚制药行业经验的法国国家药学科学院院士Joseph Scheeren对中国发展路径给予乐观评价。
Read in CHINADAILY APP : US-China biotech summit builds bridges for innovative drug partners
